First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
The EXCLAIM-2 trial did not meet its primary end point. The efficacy of mobocertinib was not superior to platinum-based chemotherapy for first-line treatment of patients with <i>EGFR</i> ex20ins+ advanced/metastatic NSCLC.
Authors
- Junjing Lin (ORCID: https://orcid.org/0000-0002-7448-2984)
- Jianchang Lin (ORCID: https://orcid.org/0000-0002-9123-0690)
- Maximilian J. Hochmair (ORCID: https://orcid.org/0000-0002-8673-2450)
- Huamao Mark Lin (ORCID: https://orcid.org/0000-0002-8399-8966)
- Benjamin Besse (ORCID: https://orcid.org/0000-0001-5090-8189)
- Bin-Chao Wang
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Robert J. Fram (ORCID: https://orcid.org/0000-0001-7216-3130)
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Danny Nguyen (ORCID: https://orcid.org/0000-0002-2479-2271)
- Solange Peters (ORCID: https://orcid.org/0000-0002-0412-7143)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Tony Mok (ORCID: https://orcid.org/0000-0002-8251-0551)
- Florin Vranceanu
- Nick Pavlakis (ORCID: https://orcid.org/0000-0002-1738-0316)
- Terufumi Kato (ORCID: https://orcid.org/0000-0002-5853-1424)
- Yi-Long Lung Cancer Wu (ORCID: https://orcid.org/0000-0002-3611-0258)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-4800-7776)
- Juan Li (ORCID: https://orcid.org/0000-0002-1617-3294)
- Annette Szumski
Institutions
- The University of Sydney (AU)
- City Of Hope National Medical Center (US)
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- Peking University (CN)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Kanagawa Prefectural Hospital Organization (JP)
- Peking University Cancer Hospital (CN)
- Dana-Farber Cancer Institute (US)
- Sichuan Cancer Hospital (CN)
- Stanford Medicine (US)
- Takeda (United States) (US)
- Guangdong Academy of Medical Sciences (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Guangdong Provincial People's Hospital (CN)
- Kanagawa Cancer Center
- Stanford Cancer Institute
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
- Cytel (United States) (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1200/jco-24-01269
- Citations
- 19
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 28.85
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Servier